CTOs on the Move

Rgenta Therapeutics

www.rgentatx.com

 
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Rgenta Therapeutics raised $20M on 04/02/2020
Rgenta Therapeutics raised $18M on 05/25/2021

Similar Companies

Alladapt

We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food allergens. And we built our inspiration into our name—Alladapt. Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens. Food allergy is a serious disease, with potentially life-threatening consequences. The disease has grown dramatically in recent years and now affects more than 6 million children¹ and 26 million adults² in the United States alone. Importantly, about half of people with food allergy are reactive to multiple foods, which further increases the risk of anaphylaxis due to accidental ingestion. The chronic, unpredictable components of this disease can elevate anxiety in patients and their families, and place extreme limitations on their lives. It is our goal to help patients experience more of life’s magical moments with less fear and greater confidence.

Network Biosystems

Network Biosystems, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Noxilizer

Noxilizer, Inc. provides room-temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.

ABI Inc

ABI Inc is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Skagit Valley Hospital

Skagit Valley Hospital is a Mount Vernon, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.